Genetic alterations shaping tumor response to anti-EGFR therapies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), are approved for treating specific cancers like non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and head and neck cancer.
• These therapies are effective only in patients with specific genetic alterations, such as gain-of-function EGFR mutations or gene amplification.
• A significant challenge is the prevalence of primary resistance and the development of acquired resistance, which limit the overall clinical benefit of anti-EGFR drugs.

Purpose of the Study:

• To review the molecular mechanisms of drug resistance in cancers treated with anti-EGFR therapies.
• To focus on genetic alterations that confer resistance to FDA/EMA-approved anti-EGFR drugs.
• To discuss emerging strategies for overcoming chemoresistance to anti-EGFR treatments.

Main Methods:

• Literature review of scientific articles and clinical studies.
• Analysis of molecular mechanisms underlying resistance to EGFR-targeted therapies.
• Synthesis of information on genetic alterations causing resistance.
• Exploration of novel therapeutic approaches to circumvent resistance.

Main Results:

• Resistance to anti-EGFR drugs often arises from alterations in genes within the EGFR signaling pathway.
• These genetic alterations can bypass EGFR inhibition, leading to continued cancer cell proliferation and progression.
• Mechanisms of resistance can be intrinsic (primary) or acquired during treatment.

Conclusions:

• Understanding the genetic basis of resistance is crucial for improving anti-EGFR therapy outcomes.
• Development of novel therapeutic strategies targeting resistance mechanisms is essential.
• Future research should focus on overcoming acquired resistance to enhance the efficacy of EGFR-targeted cancer treatments.